Blood thinner study for cancer patients with low platelets
Treatments studied
Part of Blood & lymphatic, Heart & circulation, Lungs & breathing clinical trials.
This study tests if the blood thinner apixaban is safe and effective for cancer patients who have low platelets and a recent blood clot. It may offer a treatment option for those who cannot take standard blood thinners.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have active cancer (diagnosed or treated in the last 6 months).
- You have a new blood clot in your leg or lungs (within the last 28 days).
- Your platelet count is below 75,000 (before any platelet transfusions).
- You are not currently bleeding and have not had a major bleed in the past year.
- You do not have brain tumors or certain cancers (like leukemia, stomach, or bladder).
- You are 18 or older and can swallow pills.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how best to prevent and treat dangerous blood clots in people with cancer who also have very low platelets. It may help guide safer blood-thinner treatment when bleeding risk is high.
This trial tests different ways to take the blood thinner apixaban to prevent blood clots in people with cancer who are starting or switching their cancer treatment. It aims to find the best dose for safety and effectiveness.
This study compares two blood-thinning medications, edoxaban and apixaban, in people who have both cancer and a blood clot. The goal is to see which one works better and is safer for preventing another clot while treating your cancer.
This trial tests if apixaban, a blood thinner pill, can prevent dangerous blood clots in people with advanced lung cancer who are receiving outpatient chemotherapy or other systemic treatments. It aims to reduce the risk of venous thromboembolism (blood clots in veins) during cancer therapy.
This trial studies the safety of managing blood thinners (like apixaban or warfarin) around the time of cancer surgery or procedures. It aims to help doctors understand how to best handle these medications to reduce risks.
This trial compares lower doses of two common blood thinner pills (apixaban and rivaroxaban) to a daily injection (enoxaparin) to prevent blood clots in people receiving treatment for blood cancers like multiple myeloma, lymphoma, or certain other blood cancers.
Hear when a new Deep Vein Thrombosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.